Clinical Trial

Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

Study acronym: XYP-202401
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 1, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to provide guidance and basis for the clinical application of Xiyanping injection combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease.The secondary objectives is to evaluate the effect of Xiyanping injection on the indicators of acute exacerbation of inflammation and symptom improvement of chronic obstructive pulmonary disease.
Trial Details
NCT Number NCT06754865
Lead Sponsor Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Conditions Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Enrollment 1,140 participants
Start Date 2024-12
Primary Completion 2025-11 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2025-01-01